Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Jul. 31, 2012
Jul. 31, 2011
Jul. 31, 2010
Revenues:      
Clinical laboratory services $ 59,403 $ 52,762 $ 44,178
Product revenues 37,722 41,830 43,111
Royalty and license fee income 5,958 7,437 9,793
Total revenues 103,083 102,029 97,082
Operating expenses:      
Cost of clinical laboratory services 36,305 31,682 29,570
Cost of product revenues 19,668 22,137 22,547
Research and development 6,293 7,806 9,704
Selling, general, and administrative 47,928 45,191 48,395
Provision for uncollectible accounts receivable 5,104 4,431 3,480
Legal 3,724 3,710 1,746
Litigation settlement and related costs     3,698
Impairment charges 24,540    
Total operating expenses 143,562 114,957 119,140
Operating loss (40,479) (12,928) (22,058)
Other income (expense):      
Interest 21 11 19
Other 77 45 44
Foreign exchange (loss) gain (540) 49 (266)
Loss before income taxes (40,921) (12,823) (22,261)
Benefit (provision) for income taxes 1,652 (137) 28
Net loss $ (39,269) $ (12,960) $ (22,233)
Net loss per common share:      
Basic and diluted (in Dollars per share) $ (1.01) $ (0.34) $ (0.59)
Weighted average common shares outstanding:      
Basic and diluted (in Shares) 38,798 38,357 38,001